0001136261-22-000249.txt : 20220602 0001136261-22-000249.hdr.sgml : 20220602 20220602162945 ACCESSION NUMBER: 0001136261-22-000249 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220601 FILED AS OF DATE: 20220602 DATE AS OF CHANGE: 20220602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Connor Daniel J. CENTRAL INDEX KEY: 0001376847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 22991206 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER NAME: FORMER CONFORMED NAME: O'Connor Daniel DATE OF NAME CHANGE: 20060928 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 ownership.xml X0306 4 2022-06-01 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001376847 O'Connor Daniel J. C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 1 0 0 0 Common Stock 2022-06-01 4 P 0 16000 0.6118 A 16000 D The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $0.6054 per share to $0.6127 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price. Exhibit 24 - Power of Attorney /s/ Michael Golembiewski, as attorney-in-fact for Daniel J. O'Connor 2022-06-02 EX-24 2 exh24.htm POWER OF ATTORNEY

 

Exhibit 24

 

POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints each of Raj Mehra, Ph.D. and Michael Golembiewski, signing singly, the undersigned’s true and lawful attorney-in-fact and agent to:

 

(1)        execute for and on behalf of the undersigned, an officer, director and/or holder of 10% or more of a registered class of securities of Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder;

 

(2)        do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 and 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority, as required; and

 

(3)        take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect with respect to the undersigned until the earliest to occur of (a) such date that the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, or (b) the revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. This Power of Attorney shall terminate with respect to each of the foregoing attorneys-in-fact at such time as such attorney-in-fact is no longer employed by the Company or any of its subsidiaries.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 11, 2022.

 

 

 

/s/ Daniel J. O’Connor, J.D.

Signature

 

Name: Daniel J. O’Connor, J.D.